Relmada Therapeutics to Present at Jefferies London Healthcare Conference
Conference being held November 19-21, 2024
CORAL GABLES, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer (CEO), will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024.
Jefferies London Healthcare Conference details:
| Presentation: | Wednesday, November 20, 2024 at 12:00 PM GMT |
| Speaker: | Sergio Traversa, CEO |
| Registration: | Webcast link |
The replay of the webcast will be available on the “For Investors/Events” page of the Relmada website for 90 days following the conference.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. The Company is also developing REL-P11, a proprietary low-dose psilocybin, as an investigational agent for metabolic disease. Learn more atwww.relmada.com.
Investor Contact:Tim McCarthyLifeSci AdvisorsTim@LifeSciAdvisors.com
Media Inquiries:Corporate Communicationsmedia@relmada.com
Released November 19, 2024